CytoDyn Inc.

CytoDyn Inc. (CYDY) is a publicly traded clinical-stage biotechnology company. Its work centers on leronlimab (PRO 140), a humanized monoclonal antibody CCR5 receptor antagonist being developed as a platform drug with potential in a variety of indications in solid-tumor oncology. The company states that the CCR5 receptor is implicated in a broad range of disease states, including infection, tumor metastasis, and immune signaling, and it also strategically works with select partners to explore leronlimab's potential benefits in certain inflammatory diseases. CytoDyn describes its purpose as improving patients' quality of life through therapeutic innovation.

CytoDyn Inc. is a publicly traded clinical-stage biotechnology company. Its development work centers on leronlimab (PRO 140), a humanized monoclonal antibody CCR5 receptor antagonist. The company states that the CCR5 receptor is a protein located on the surface of a variety of cells including white blood cells and cancer cells, and that recent research has identified it as an important target for many disease processes including cancer metastasis and certain immunological conditions. CytoDyn is focused on CCR5 and its role in the treatment of solid-tumor oncology, and it also strategically works with select partners to explore leronlimab's potential benefits in certain inflammatory diseases. The company has reported a Phase 2 CRC trial and a Phase 2a study in collaboration with Weill Cornell Medicine evaluating leronlimab in Alzheimer's disease, and announced the closing of a $16.5 million financing to fund continued development of leronlimab.

Clinical-stage biotechnology company developing leronlimab as a paradigm-shifting therapeutic and platform drug targeting the CCR5 receptor, focused on solid-tumor oncology.

• Leronlimab (PRO 140)

  A humanized monoclonal antibody CCR5 receptor antagonist being developed as a platform drug with potential in a variety of indications in solid-tumor oncology; preclinical research has shown it blocks calcium channel signaling of the CCR5 receptor when present on the cancer cell surface.

1. 1CytoDyn Inc. (CYDY)cytodyn.com
2. 2About :: CytoDyn Inc. (CYDY)cytodyn.com
3. 3Our Mission :: CytoDyn Inc. (CYDY)cytodyn.com